NanoBio to Present Preclinical Data in the Development of Novel Topical Treatments for Acne and Fungal Infections

NanoBio Corporation announced today that it will present compelling new data highlighting preclinical milestones in the development of its novel topical treatments for acne and fungal infections. The new data will be delivered in three poster presentations during the 2009 annual meeting of the Society of Investigative Dermatology in Montreal, Canada, from May 6-9, 2009.

Poster Presentations, Room 220 D/E, 10:00 a.m. – 12:00 p.m.:

Thursday, May 7, 2009

Poster # 464: In-vitro Skin Penetration of Novel Antimicrobial Nanoemulsion Formulations Containing Antifungal Agents
Poster # 616: In-vitro Susceptibility of Propionibacterium acnes and Skin Penetration of NB-00X Formulations

Saturday, May 9, 2009

Poster # 465: Lateral Diffusion of Terbinafine Hydrochloride in a Novel Nanoemulsion

NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines.

The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback